期刊
CURRENT ONCOLOGY
卷 28, 期 6, 页码 4317-4327出版社
MDPI
DOI: 10.3390/curroncol28060367
关键词
hepatocellular cancer; local therapy; TACE; SABR; systemic therapy; immunotherapy
类别
资金
- Pfizer
- Hoffmann-La Roche
- AstraZeneca Canada
- Roche
- Eisai
- Bristol Myers Squibb
- Merck Inc.
- Taiho Canada
The Fifth Western Canadian Gastrointestinal Cancer Consensus Conference convened virtually on February 10, 2021. The conference aimed to address current issues in the management of hepatocellular cancer (HCC) and provided recommendations for the transition from local to systemic therapy and the optimal sequencing of systemic regimens for HCC.
The Western Canadian Gastrointestinal Cancer Consensus Conference (WC-5) convened virtually on 10 February 2021. The WC-5 is an interactive multidisciplinary conference attended by health care professionals from across Western Canada (British Columbia, Alberta, Saskatchewan, and Manitoba) who are involved in the care of patients with gastrointestinal cancer. Surgical, medical, and radiation oncologists; pathologists; radiologists; and allied health care professionals participated in presentation and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses current issues in the management of hepatocellular cancer (HCC). Recommendations have been made for the transition from local to systemic therapy and the optimal sequencing of systemic regimens in the management of HCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据